The second interim analysis is from September 2023 and is referred to as the second data cut from here. It compares dostarlimab plus carboplatin with paclitaxel (from now, dostarlimab) with placebo ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all development and ongoing trials.

Getty Images A new clinical trial shows the immunotherapy drug dostarlimab could eliminate the need for surgery and chemotherapy in certain cancers. The results are a medical breakthrough since ...

Cercek et al. carried out a phase 2 trial in which patients with early-stage dMMR solid tumors amenable to surgery (with curative intent) were treated with neoadjuvant dostarlimab (anti-PD-1 ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...